A new drug that extends the lives of patients with advanced breast cancer has been hailed as a “landmark moment” in medicine.
Capivasertib blocks a key cancer -driving protein and when combined with hormone therapy doubled the time patients had without their tumours progressing.
It could benefit 8,000 women in the UK each year with ER positive HER-2 negative breast cancer, which accounts for 70% of new cases.
